Ishida S, Usui T, Yamashiro K, et al: VEGF 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198: 483-489, 2003.
Ishida S, Usui T, Yamashiro K, et al: VEGF 164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 44: 2155-2162, 2003.
Gragoudas ES, Adamis AP, Cunningham ET Jr, et al: VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816, 2004.
Rosenfeld PJ, Brown DM, Heier JS, et al: MARINA Study Group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431, 2006.
Ueta T, Yanagi Y, Tamaki Y, et al: Cerebrovascular accidents in ranibizumab. Ophthalmology 116: 362, 2009.